Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646933 | 0.89 | KMT2A (0.57) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL29583255 | 0.89 | KMT2A (0.57) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL70381 | 0.88 | BRD4 (0.59) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL29434198 | 0.88 | BRD4 (0.59) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL1518036 | 0.85 | PRNP (0.47) | RXFP1PKMLMNAKDM4EALDH1A1 | |
| SCHEMBL18302011 | 0.83 | SLC6A3 (0.56) | RXFP1PKMNR4A2CREBBPLMNA | |
| SCHEMBL1599297 | 0.82 | PKM (0.47) | RXFP1PKMLMNAKDM4EALDH1A1 | |
| SCHEMBL31049726 | 0.81 | BRD4 (0.53) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL5750893 | 0.81 | BRD4 (0.53) | BRD4NR4A2CREBBPLMNATSHR | |
| SCHEMBL31049722 | 0.81 | BRD4 (0.53) | BRD4NR4A2CREBBPLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011423-A | Zirconium-based metal organic framework material and preparation method and application thereof | 苏州科技大学 | 2026-05-12 | — | — | CN | claimed |
| CN-119306594-A | Dinaphthalene anthracene compound, synthesis method thereof and application thereof in preparing seawater uranium extraction MOF (30-Zr) | 中国石油大学(华东) | 2025-01-14 | — | — | CN | claimed |
| CN-122011423-A | Zirconium-based metal organic framework material and preparation method and application thereof | 苏州科技大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250388625-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4543902-A1 | CYCLOSPORINE ANALOGUES | UCL Business Ltd (GB) | 2025-04-30 | — | — | EP | disclosed |
| CN-119768419-A | Cyclosporin analogs | UCL商业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119306594-A | Dinaphthalene anthracene compound, synthesis method thereof and application thereof in preparing seawater uranium extraction MOF (30-Zr) | 中国石油大学(华东) | 2025-01-14 | — | — | CN | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118239923-A | Compounds useful as inhibitors of factor XIIa, pharmaceutical compositions and uses thereof | 合肥工业大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-117736182-A | MetTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023247937-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2023-12-28 | — | — | WO | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1216239-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-26 | — | — | EP | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2001023374-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | BRD4 1816/4885RXFP1 1875/4885PKM 3800/4885 |
| US-20250388625-A1 | CYCLOSPORINE ANALOGUES | MALT1, CHP1, CCR1 | BRD4 3794/4885RXFP1 2684/4885PKM 4841/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | BRD4 71/4885RXFP1 4793/4885PKM 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.